| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
6.69(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,765 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
76,725 |
242,570 |
415,590 |
896,412 |
| Total Sell Value |
$4,996,032 |
$17,279,646 |
$23,096,957 |
$44,570,423 |
| Total People Sold |
4 |
6 |
7 |
11 |
| Total Sell Transactions |
5 |
17 |
37 |
83 |
| End Date |
2024-03-08 |
2023-12-06 |
2023-06-07 |
2022-06-07 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Blum Robert I |
President & CEO |
• • – |
2021-10-29 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
365,063 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• – – |
2021-10-19 |
4 |
AS |
$35.73 |
$1,275,186 |
D/D |
(35,687) |
53,064 |
|
7% |
|
| Parshall B Lynne |
Director |
– • – |
2021-10-19 |
4 |
AS |
$35.73 |
$369,207 |
D/D |
(10,332) |
5,000 |
|
7% |
|
| Parshall B Lynne |
Director |
– • – |
2021-10-19 |
4 |
OE |
$6.60 |
$68,671 |
D/D |
10,332 |
13,333 |
|
- |
|
| Schlossberg Mark A |
SVP - Legal & General Counsel |
• – – |
2021-10-19 |
4 |
AS |
$35.74 |
$713,970 |
D/D |
(19,979) |
50,850 |
|
7% |
|
| Schlossberg Mark A |
SVP - Legal & General Counsel |
• – – |
2021-10-19 |
4 |
OE |
$7.03 |
$140,452 |
D/D |
19,979 |
70,829 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2021-10-14 |
4 |
AS |
$37.74 |
$188,713 |
D/D |
(5,000) |
357,563 |
|
-8% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-10-14 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
362,563 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2021-10-14 |
4 |
AS |
$37.73 |
$75,452 |
D/D |
(2,000) |
150,878 |
|
-8% |
|
| Califf Robert |
Director |
– • – |
2021-10-01 |
4 |
A |
$36.74 |
$5,621 |
D/D |
153 |
5,881 |
|
- |
|
| Smith Sandford D |
Director |
– • – |
2021-10-01 |
4 |
A |
$36.74 |
$11,242 |
D/D |
306 |
6,765 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2021-10-01 |
4 |
A |
$36.74 |
$18,737 |
D/D |
510 |
28,932 |
|
- |
|
| Wierenga Wendall D |
Director |
– • – |
2021-10-01 |
4 |
A |
$36.74 |
$11,242 |
D/D |
306 |
6,765 |
|
- |
|
| Kaye Edward M. Md |
Director |
– • – |
2021-10-01 |
4 |
A |
$36.74 |
$11,242 |
D/D |
306 |
6,765 |
|
- |
|
| Wysenski Nancy |
Director |
– • – |
2021-10-01 |
4 |
A |
$36.74 |
$5,621 |
D/D |
153 |
5,881 |
|
- |
|
| Henderson John T |
Director |
– • – |
2021-10-01 |
4 |
A |
$36.74 |
$11,242 |
D/D |
306 |
13,255 |
|
- |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2021-10-01 |
4 |
AS |
$35.14 |
$265,990 |
D/D |
(7,569) |
137,123 |
|
10% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-30 |
4 |
AS |
$34.01 |
$170,064 |
D/D |
(5,000) |
357,563 |
|
10% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-30 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
362,563 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-15 |
4 |
AS |
$32.66 |
$163,317 |
D/D |
(5,000) |
357,563 |
|
-10% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-15 |
4 |
OE |
$6.00 |
$31,220 |
D/D |
5,000 |
361,628 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2021-09-09 |
4 |
AS |
$31.43 |
$62,860 |
D/D |
(2,000) |
152,878 |
|
3% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-02 |
4 |
AS |
$33.12 |
$165,577 |
D/D |
(5,000) |
357,563 |
|
-2% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-02 |
4 |
OE |
$6.30 |
$31,500 |
D/D |
5,000 |
362,563 |
|
- |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2021-09-01 |
4 |
AS |
$32.78 |
$257,311 |
D/D |
(7,850) |
144,692 |
|
3% |
|
1108 Records found
|
|
Page 15 of 45 |
|
|
6.17 (12.75%) 
